Infertility (IVF Patients)MaLIV-PMANCT06884930
Machine Learning and Pregnancy Success Prediction in Fertility Treatments
An observational study of Infertility (IVF Patients), run by IRCCS San Raffaele at 1 site in Italy.
Trial summary
Infertility, as defined by the World Health Organization (WHO), is a disorder of the male or female reproductive system characterized by the inability to achieve a clinical pregnancy after 12 months or more of regular, unprotected sexual intercourse. Read more about this study
- Who is it for?
- Ages 18 to 43 years
- Conditions the study is for
- Infertility (IVF Patients)
- How many people
- 5,000 participants
- Where
- 1 siteItaly
- Study dates
- 16 Apr 2025to Mar 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 43 years
- All sexes
- No healthy volunteers
- Adult
Study population: Couples who received IVF treatment between 2019 and 2024
Who may be able to join
- Patients who underwent ART procedures, including IVF and ICSI, between 2019 and 2024.
- Women aged between 18 and 43 years.
Who cannot join
- Patiens with incomplete or missing data records that do not provide sufficient information for analysis.
- women outside the 18 to 43 age range
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Machine Learning-based Evaluation of Pregnancy Success Indicators in Assisted Reproductive Technology (ART) Cycles
Infertility, as defined by the World Health Organization (WHO), is a disorder of the male or female reproductive system characterized by the inability to achieve a clinical pregnancy after 12 months or more of regular, unprotected sexual intercourse. In modern fertility treatment, assisted reproductive technologies (ART), including in vitro fertilization (IVF), have become a standard approach for addressing complex fertility issues and sterility. In Italy, infertility affects approximately 16.5% of couples.
Despite advancements in ART, comparing the failure rates of pregnancies achieved through ART with those of spontaneous pregnancies in Italy reveals significant differences, particularly in terms of success rates, miscarriage rates, and embryo implantation outcomes.
Read more
In this context, AI-based models have shown promising potential in predicting IVF success by analyzing complex datasets that include patient demographics, hormonal levels, and embryo morphology. Research indicates that AI can enhance embryo selection, predict the optimal timing for embryo transfer, and advance personalized medicine approaches in reproductive health.
This study aims to use of Machine Learning to identify patterns and factors associated with successful pregnancy outcomes by analyzing large-scale, anonymized ART data. The resulting predictive model could enable clinicians to better personalize treatment protocols for each patient, optimizing medication dosages, timing, and embryo selection. It could also improve pregnancy success rates while reducing the emotional and financial burden on patients, thus advancing the standard of care in ART.
Read the detailed description
This is a multicentric, observational, retrospective, non-profit study, coordinated by the IRCCS San Raffaele Hospital, aims to analyze anonymized data collected between 2019 and 2024 from approximately 5,000 couples undergoing Assisted Reproductive Technology (ART) procedures across three participating centers. The study will examine key variables, including age, medical history, treatment protocols, ART techniques (such as In Vitro Fertilization [IVF] and Intracytoplasmic Sperm Injection [ICSI]), embryo quality, and pregnancy outcomes, to develop a machine learning-based predictive model for pregnancy outcomes. The selected timeframe ensures a sufficiently large dataset to facilitate robust development and validation of the predictive model.
By leveraging machine learning techniques, this study aims to enhance the accuracy of pregnancy outcome predictions, thereby improving patient counseling and treatment planning in ART procedures. The comprehensive dataset, encompassing a diverse range of variables and a substantial number of cases, will provide a robust foundation for developing a predictive model with high clinical applicability.
The primary objective of this study is to develop a Machine Learning-based predictive model for pregnancy outcomes in assisted reproductive technologies (ART), by analyzing large-scale, anonymized data, for scientific research purposes. The model aims to identify key patterns and factors that correlate with successful pregnancy outcomes to optimize individualized treatment protocols for patients undergoing ART.
SAMPLE SIZE:
The sample size will be approximately 5,000 pairs of subjects (women + men) based on the total number of ART cycles recorded at the participating centers during this period and the number of patients with complete data records that provide sufficient information for analysis. We expect approximately 1650 pairs for the class "success" and 3350 for the class "unsuccess" of the IVF treatment. Thus, the Machine Learning-based predictive model could be trained using a multi-parametric approach with a balanced set of 1350 pairs of subjects, using the remaining couples of subjects to test the performance of the model.
The minimum sample size for the retrospective study should be 295 pairs of subjects, calculated to yield a 95% confidence interval of ± 2.5% around an expected sensitivity of 94% and an expected specificity of 15% of the prediction model, with a prevalence of IVF treatment success of 30% and a dropout rate of 2%. This success prevalence is expected based on the clinical site's experience of the number of IVF treatments; the dropout rate is considered low, at 2%, considering the type of retrospective clinical study using software and the residual possibility of complete data not being valid. Sensitivity, specificity, positive and negative predictive values are calculated with their 95% confidence intervals.
Considering the minimum sample size and the available number of samples, we expect to achieve statistical significance from the hypothesis testing and to obtain a multi-modal signature of predictors of IVF success.
STATISTICAL DESIGN A structured methodology will be employed to develop and assess machine learning models for binary classification tasks, specifically distinguishing between "Success" and "Not Success." The process will commence with the selection of informative and non-redundant features, eliminating those with low variance and high correlation. Subsequently, three distinct classifier models-Random Forest, Support Vector Machines (SVM), and K-Nearest Neighbors (KNN)-will be trained and evaluated using k-fold cross-validation to ensure robust performance assessment. To address potential data imbalances, the ADASYN technique will be applied, generating synthetic samples for the minority class. Model performance will be quantified using various metrics, including accuracy, sensitivity, specificity, and the area under the receiver operating characteristic curve (ROC-AUC), to identify the most effective model. Finally, a statistical analysis of the most pertinent features will be conducted using non-parametric tests and corrections for multiple comparisons, aiming to elucidate class differences and ensure result reliability.
This structured approach will ensure that the models are meticulously tuned and validated through rigorous testing and analysis, leading to accurate and reliable machine learning models for binary classification tasks.
INFORMED CONSENT AND DATA PROTECTION In accordance with data protection regulations, the study will utilize anonymized data previously collected through routine clinical practice and stored in MedITEX IVF, a management software used at the participating assisted reproduction centers. No direct patient interaction or intervention will occur as part of the study. All data will be anonymized following best practice guidelines to ensure patient confidentiality, adhering to ethical standards and applicable data privacy regulations.
The Investigator (or the Center receiving the data) commits to processing the data solely for the purposes of the study, storing it in a secure network system, and restricting access to authorized personnel who have undertaken confidentiality agreements. If external suppliers are involved, they will be appointed as Data Processors with appropriate agreements in place. The Investigator will also facilitate the exercise of data subject rights, including access, rectification, cancellation, limitation, opposition, and portability, within 30 days of receiving the relevant request. In the event of data communication outside the institution in pseudonymized form, efforts will be made to prevent the identification of data subjects. Within 30 days following the end of the study, the Investigator will ensure the deletion or irreversible anonymization of the communicated data and promptly communicate this in writing.
A study-specific Data Protection Impact Assessment (DPIA), reviewed by the Data Protection Officer (DPO) of the coordinating institution, has been conducted in accordance with applicable data protection laws.
- Conditions
- Infertility (IVF Patients)
- Keywords
- IVF, Machine Learning-based Predictive Model, pregnancy
- Medical subject headings
- Infertility
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| IVF patients | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pregnancy rate
The primary endpoint of the study will be the clinical pregnancy defined as a pregnancy confirmed by an increasing level of hCG and the presence of a gestational sac or heartbeat detected by ultrasound.
Measured: Data will be extracted for all ART cycles conducted between 2019 and 2024 to allow for the comprehensive development of the Machine Learning-based model.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Mar 2025
- Study start16 Apr 2025
- Primary completionMar 2026 (estimated)
- Study completionMar 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Infertility (IVF Patients)Studies of the same condition, open and under way.
- More trials run by IRCCS San RaffaeleThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Retrospective
- Enrolment
- 5,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- IRCCS San Raffaele
- Sponsor type
- University, hospital or other
- Collaborators
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, ASST Grande Ospedale Metropolitano Niguarda
- Responsible party
- Principal investigator, Enrico Papaleo, IRCCS San Raffaele
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06884930
- Sponsor's protocol ID
- MaLIV-PMA
- Acronym
- MaLIV-PMA
- Status last verified
- Oct 2025
- First submitted
- 13 Mar 2025
- Last updated
- 7 Oct 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Zhang Q, Liang X, Chen Z. A review of artificial intelligence applications in in vitro fertilization. J Assist Reprod Genet. 2025 Jan;42(1):3-14. doi: 10.1007/s10815-024-03284-6. Epub 2024 Oct 14.
PubMed 39400647Jiang VS, Bormann CL. Artificial intelligence in the in vitro fertilization laboratory: a review of advancements over the last decade. Fertil Steril. 2023 Jul;120(1):17-23. doi: 10.1016/j.fertnstert.2023.05.149. Epub 2023 May 19.
PubMed 37211062Attività del Registro Nazionale Italiano della Procreazione Medicalmente Assistita - 17° Report 2021
European IVF Monitoring Consortium (EIM) for the European Society of Human Reproduction and Embryology (ESHRE); Smeenk J, Wyns C, De Geyter C, Kupka M, Bergh C, Cuevas Saiz I, De Neubourg D, Rezabek K, Tandler-Schneider A, Rugescu I, Goossens V. ART in Europe, 2019: results generated from European registries by ESHREdagger. Hum Reprod. 2023 Dec 4;38(12):2321-2338. doi: 10.1093/humrep/dead197.
PubMed 37847771Infertility prevalence estimates, 1990-2021. Geneva: World Health Organization; 2023. Licence: CC BY-NC-SA 3.0 IGO.
Study at a glance
From the registry record, last updated by the sponsor on 7 Oct 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Machine Learning-based Evaluation of Pregnancy Success Indicators in Assisted Reproductive Technology (ART) Cycles
- ClinicalTrials.gov ID
- NCT06884930
- Acronym / sponsor ID
- MaLIV-PMA / MaLIV-PMA
- Conditions
- Infertility (IVF Patients)
- Keywords
- IVF, Machine Learning-based Predictive Model, pregnancy
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 5,000 participants (estimated)
- Lead sponsor
- IRCCS San RaffaeleUniversity, hospital or other
- Collaborators
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, ASST Grande Ospedale Metropolitano Niguarda
- Study start
- 16 Apr 2025 (actual)
- Primary completion
- Mar 2026 (estimated)
- Study completion
- Mar 2026 (estimated)
- First posted
- 19 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Infertility, as defined by the World Health Organization (WHO), is a disorder of the male or female reproductive system characterized by the inability to achieve a clinical pregnancy after 12 months or more of regular, unprotected sexual intercourse. In modern fertility treatment, assisted reproductive technologies (ART), including in vitro fertilization (IVF), have become a standard approach for addressing complex fertility issues and sterility. In Italy, infertility affects approximately 16.5% of couples.
Despite advancements in ART, comparing the failure rates of pregnancies achieved through ART with those of spontaneous pregnancies in Italy reveals significant differences, particularly in terms of success rates, miscarriage rates, and embryo implantation outcomes.
In this context, AI-based models have shown promising potential in predicting IVF success by analyzing complex datasets that include patient demographics, hormonal levels, and embryo morphology. Research indicates that AI can enhance embryo selection, predict the optimal timing for embryo transfer, and advance personalized medicine approaches in reproductive health.
This study aims to use of Machine Learning to identify patterns and factors associated with successful pregnancy outcomes by analyzing large-scale, anonymized ART data. The resulting predictive model could enable clinicians to better personalize treatment protocols for each patient, optimizing medication dosages, timing, and embryo selection. It could also improve pregnancy success rates while reducing the emotional and financial burden on patients, thus advancing the standard of care in ART.
Detailed description
This is a multicentric, observational, retrospective, non-profit study, coordinated by the IRCCS San Raffaele Hospital, aims to analyze anonymized data collected between 2019 and 2024 from approximately 5,000 couples undergoing Assisted Reproductive Technology (ART) procedures across three participating centers. The study will examine key variables, including age, medical history, treatment protocols, ART techniques (such as In Vitro Fertilization [IVF] and Intracytoplasmic Sperm Injection [ICSI]), embryo quality, and pregnancy outcomes, to develop a machine learning-based predictive model for pregnancy outcomes. The selected timeframe ensures a sufficiently large dataset to facilitate robust development and validation of the predictive model.
By leveraging machine learning techniques, this study aims to enhance the accuracy of pregnancy outcome predictions, thereby improving patient counseling and treatment planning in ART procedures. The comprehensive dataset, encompassing a diverse range of variables and a substantial number of cases, will provide a robust foundation for developing a predictive model with high clinical applicability.
The primary objective of this study is to develop a Machine Learning-based predictive model for pregnancy outcomes in assisted reproductive technologies (ART), by analyzing large-scale, anonymized data, for scientific research purposes. The model aims to identify key patterns and factors that correlate with successful pregnancy outcomes to optimize individualized treatment protocols for patients undergoing ART.
SAMPLE SIZE:
The sample size will be approximately 5,000 pairs of subjects (women + men) based on the total number of ART cycles recorded at the participating centers during this period and the number of patients with complete data records that provide sufficient information for analysis. We expect approximately 1650 pairs for the class "success" and 3350 for the class "unsuccess" of the IVF treatment. Thus, the Machine Learning-based predictive model could be trained using a multi-parametric approach with a balanced set of 1350 pairs of subjects, using the remaining couples of subjects to test the performance of the model.
The minimum sample size for the retrospective study should be 295 pairs of subjects, calculated to yield a 95% confidence interval of ± 2.5% around an expected sensitivity of 94% and an expected specificity of 15% of the prediction model, with a prevalence of IVF treatment success of 30% and a dropout rate of 2%. This success prevalence is expected based on the clinical site's experience of the number of IVF treatments; the dropout rate is considered low, at 2%, considering the type of retrospective clinical study using software and the residual possibility of complete data not being valid. Sensitivity, specificity, positive and negative predictive values are calculated with their 95% confidence intervals.
Considering the minimum sample size and the available number of samples, we expect to achieve statistical significance from the hypothesis testing and to obtain a multi-modal signature of predictors of IVF success.
STATISTICAL DESIGN A structured methodology will be employed to develop and assess machine learning models for binary classification tasks, specifically distinguishing between "Success" and "Not Success." The process will commence with the selection of informative and non-redundant features, eliminating those with low variance and high correlation. Subsequently, three distinct classifier models-Random Forest, Support Vector Machines (SVM), and K-Nearest Neighbors (KNN)-will be trained and evaluated using k-fold cross-validation to ensure robust performance assessment. To address potential data imbalances, the ADASYN technique will be applied, generating synthetic samples for the minority class. Model performance will be quantified using various metrics, including accuracy, sensitivity, specificity, and the area under the receiver operating characteristic curve (ROC-AUC), to identify the most effective model. Finally, a statistical analysis of the most pertinent features will be conducted using non-parametric tests and corrections for multiple comparisons, aiming to elucidate class differences and ensure result reliability.
This structured approach will ensure that the models are meticulously tuned and validated through rigorous testing and analysis, leading to accurate and reliable machine learning models for binary classification tasks.
INFORMED CONSENT AND DATA PROTECTION In accordance with data protection regulations, the study will utilize anonymized data previously collected through routine clinical practice and stored in MedITEX IVF, a management software used at the participating assisted reproduction centers. No direct patient interaction or intervention will occur as part of the study. All data will be anonymized following best practice guidelines to ensure patient confidentiality, adhering to ethical standards and applicable data privacy regulations.
The Investigator (or the Center receiving the data) commits to processing the data solely for the purposes of the study, storing it in a secure network system, and restricting access to authorized personnel who have undertaken confidentiality agreements. If external suppliers are involved, they will be appointed as Data Processors with appropriate agreements in place. The Investigator will also facilitate the exercise of data subject rights, including access, rectification, cancellation, limitation, opposition, and portability, within 30 days of receiving the relevant request. In the event of data communication outside the institution in pseudonymized form, efforts will be made to prevent the identification of data subjects. Within 30 days following the end of the study, the Investigator will ensure the deletion or irreversible anonymization of the communicated data and promptly communicate this in writing.
A study-specific Data Protection Impact Assessment (DPIA), reviewed by the Data Protection Officer (DPO) of the coordinating institution, has been conducted in accordance with applicable data protection laws.
Study design
- Observational model
- Other
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| IVF patients | – | – |
Who may qualify
- Ages
- 18 to 43 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- Couples who received IVF treatment between 2019 and 2024
Key inclusion criteria (2 listed)
- Patients who underwent ART procedures, including IVF and ICSI, between 2019 and 2024.
- Women aged between 18 and 43 years.
Key exclusion criteria (2 listed)
- Patiens with incomplete or missing data records that do not provide sufficient information for analysis.
- women outside the 18 to 43 age range
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Pregnancy rate
Time frame: Data will be extracted for all ART cycles conducted between 2019 and 2024 to allow for the comprehensive development of the Machine Learning-based model.
The primary endpoint of the study will be the clinical pregnancy defined as a pregnancy confirmed by an increasing level of hCG and the presence of a gestational sac or heartbeat detected by ultrasound.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Oct 2025.
- Results publication: PubMed 39400647Zhang Q, Liang X, Chen Z. A review of artificial intelligence applications in in vitro fertilization. J Assist Reprod Genet. 2025 Jan;42(1):3-14. doi: 10.1007/s10815-024-03284-6. Epub 2024 Oct 14.
- Results publication: PubMed 37211062Jiang VS, Bormann CL. Artificial intelligence in the in vitro fertilization laboratory: a review of advancements over the last decade. Fertil Steril. 2023 Jul;120(1):17-23. doi: 10.1016/j.fertnstert.2023.05.149. Epub 2023 May 19.
- Results publicationAttività del Registro Nazionale Italiano della Procreazione Medicalmente Assistita - 17° Report 2021
- Results publication: PubMed 37847771European IVF Monitoring Consortium (EIM) for the European Society of Human Reproduction and Embryology (ESHRE); Smeenk J, Wyns C, De Geyter C, Kupka M, Bergh C, Cuevas Saiz I, De Neubourg D, Rezabek K, Tandler-Schneider A, Rugescu I, Goossens V. ART in Europe, 2019: results generated from European registries by ESHREdagger. Hum Reprod. 2023 Dec 4;38(12):2321-2338. doi: 10.1093/humrep/dead197.
- Results publicationInfertility prevalence estimates, 1990-2021. Geneva: World Health Organization; 2023. Licence: CC BY-NC-SA 3.0 IGO.
- Individual participant dataSharing planned: No
Related trials for Infertility (IVF Patients)
RecruitingObservational study
Pilot Study of Discarded Blastocysts
Infertility (IVF Patients)
Active, not recruitingPhase 3
Human Menopausal Gonadotropin Research in Infertility Assessing Cumulative Live Birth With Frozen Embryo Transfer.
Infertility (IVF Patients)
Recruiting
225 IU Versus 300 IU Starting FSH Dose in PPOS for Good-Prognosis Women
Infertility (IVF Patients), Infertility Assisted Reproductive Technology
Recruiting
The Effects of Carnitine Supplementation on Oocytes in Women Undergoing IVF Process
Infertility (IVF Patients)
Not yet recruiting
Intra-ovarian CAPA-IVM vs Standard IVM
Infertility (IVF Patients), Infertility
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Infertility (IVF Patients), run by IRCCS San Raffaele at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 7 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pregnancy rate (time frame: Data will be extracted for all ART cycles conducted between 2019 and 2024 to allow for the comprehensive development of the Machine Learning-based model.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06884930, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Oct 2025.